Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
646 patients who underwent curative-intent surgery, 25 met the eligibility criteria and received adjuvant atezolizumab.
I · Intervention 중재 / 시술
at least one cycle of adjuvant atezolizumab after platinum-based chemotherapy between January 2021 and December 2024
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
[BACKGROUND] Postoperative atezolizumab is approved as adjuvant therapy for programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in Japan, based on the phase III IMpower010 tr
- 추적기간 27.4 months
- 연구 설계 cohort study
APA
Nakamura A, Kondo N, et al. (2026). Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.. Journal of thoracic disease, 18(3), 217. https://doi.org/10.21037/jtd-2025-1-2564
MLA
Nakamura A, et al.. "Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.." Journal of thoracic disease, vol. 18, no. 3, 2026, pp. 217.
PMID
41988310
Abstract
[BACKGROUND] Postoperative atezolizumab is approved as adjuvant therapy for programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in Japan, based on the phase III IMpower010 trial. However, real-world data on this therapeutic approach remains limited. This study aimed to evaluate the real-world effectiveness and safety of adjuvant atezolizumab in patients with pathological stage II-III NSCLC.
[METHODS] This single-institution retrospective cohort study included patients with completely resected pathological stage IIA-IIIB [Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system version 8] NSCLC who received at least one cycle of adjuvant atezolizumab after platinum-based chemotherapy between January 2021 and December 2024. Clinical characteristics, treatment completion, disease-free survival (DFS), overall survival (OS), and adverse events (AEs) were evaluated. Survival outcomes were estimated using the Kaplan-Meier method.
[RESULTS] Among 646 patients who underwent curative-intent surgery, 25 met the eligibility criteria and received adjuvant atezolizumab. PD-L1 expression assessed using the 22C3 assay was <1% in 1 patient, 1-49% in 11, and ≥50% in 13; notably, the patient with PD-L1 <1% on 22C3 testing was found to be positive on SP263 testing. Median follow-up was 27.4 months. Median DFS was not reached; the 2-year DFS rate was 63.8%, with comparable outcomes between PD-L1 subgroups (PD-L1 1-49%: 72.9% ≥50%: 57.7%; P=0.37). AEs occurred in 60.0%, including two grade 3 events. No grade 4-5 toxicities or treatment-related deaths were observed. Fifteen patients (60.0%) completed 1 year of treatment.
[CONCLUSIONS] In this real-world cohort, adjuvant atezolizumab demonstrated favorable tolerability and clinically meaningful DFS across PD-L1 expression subgroups, including patients with PD-L1 1-49%. These findings are descriptive in nature and should be interpreted with caution, nevertheless, they provide real-world evidence supporting the potential clinical utility of adjuvant atezolizumab in appropriately selected patients with resected stage II-III NSCLC.
[METHODS] This single-institution retrospective cohort study included patients with completely resected pathological stage IIA-IIIB [Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system version 8] NSCLC who received at least one cycle of adjuvant atezolizumab after platinum-based chemotherapy between January 2021 and December 2024. Clinical characteristics, treatment completion, disease-free survival (DFS), overall survival (OS), and adverse events (AEs) were evaluated. Survival outcomes were estimated using the Kaplan-Meier method.
[RESULTS] Among 646 patients who underwent curative-intent surgery, 25 met the eligibility criteria and received adjuvant atezolizumab. PD-L1 expression assessed using the 22C3 assay was <1% in 1 patient, 1-49% in 11, and ≥50% in 13; notably, the patient with PD-L1 <1% on 22C3 testing was found to be positive on SP263 testing. Median follow-up was 27.4 months. Median DFS was not reached; the 2-year DFS rate was 63.8%, with comparable outcomes between PD-L1 subgroups (PD-L1 1-49%: 72.9% ≥50%: 57.7%; P=0.37). AEs occurred in 60.0%, including two grade 3 events. No grade 4-5 toxicities or treatment-related deaths were observed. Fifteen patients (60.0%) completed 1 year of treatment.
[CONCLUSIONS] In this real-world cohort, adjuvant atezolizumab demonstrated favorable tolerability and clinically meaningful DFS across PD-L1 expression subgroups, including patients with PD-L1 1-49%. These findings are descriptive in nature and should be interpreted with caution, nevertheless, they provide real-world evidence supporting the potential clinical utility of adjuvant atezolizumab in appropriately selected patients with resected stage II-III NSCLC.